These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

553 related articles for article (PubMed ID: 19570025)

  • 21. [Pathogenesis of Parkinson's disease through LRRK2 mutation].
    Ohta E; Obata F
    Seikagaku; 2014 Feb; 86(1):92-7. PubMed ID: 24693706
    [No Abstract]   [Full Text] [Related]  

  • 22. LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.
    Esteves AR; Swerdlow RH; Cardoso SM
    Exp Neurol; 2014 Nov; 261():206-16. PubMed ID: 24907399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The R1441C mutation of LRRK2 disrupts GTP hydrolysis.
    Lewis PA; Greggio E; Beilina A; Jain S; Baker A; Cookson MR
    Biochem Biophys Res Commun; 2007 Jun; 357(3):668-71. PubMed ID: 17442267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leucine-rich repeat kinase 2 (LRRK2) cellular biology: a review of recent advances in identifying physiological substrates and cellular functions.
    Drolet RE; Sanders JM; Kern JT
    J Neurogenet; 2011 Dec; 25(4):140-51. PubMed ID: 22077787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The small GTPase activity of the ROC domain from LRRK2, a Parkinson's disease related protein.
    Fu QS; Song AX; Li SX; Hu HY
    Protein Pept Lett; 2009; 16(12):1442-6. PubMed ID: 20001906
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LRRK2 links genetic and sporadic Parkinson's disease.
    Kluss JH; Mamais A; Cookson MR
    Biochem Soc Trans; 2019 Apr; 47(2):651-661. PubMed ID: 30837320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rac1 protein rescues neurite retraction caused by G2019S leucine-rich repeat kinase 2 (LRRK2).
    Chan D; Citro A; Cordy JM; Shen GC; Wolozin B
    J Biol Chem; 2011 May; 286(18):16140-9. PubMed ID: 21454543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular biology changes associated with LRRK2 mutations in Parkinson's disease.
    Lu YW; Tan EK
    J Neurosci Res; 2008 Jul; 86(9):1895-901. PubMed ID: 18338801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. LRRK2 Pathways Leading to Neurodegeneration.
    Cookson MR
    Curr Neurol Neurosci Rep; 2015 Jul; 15(7):42. PubMed ID: 26008812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
    Zhang X; Kortholt A
    Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression, purification and preliminary biochemical and structural characterization of the leucine rich repeat namesake domain of leucine rich repeat kinase 2.
    Vancraenenbroeck R; Lobbestael E; Weeks SD; Strelkov SV; Baekelandt V; Taymans JM; De Maeyer M
    Biochim Biophys Acta; 2012 Mar; 1824(3):450-60. PubMed ID: 22251894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular effects of LRRK2 mutations.
    Cookson MR
    Biochem Soc Trans; 2012 Oct; 40(5):1070-3. PubMed ID: 22988867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LRRK2 Parkinson's disease: from animal models to cellular mechanisms.
    Lin CH; Tsai PI; Wu RM; Chien CT
    Rev Neurosci; 2011; 22(4):411-8. PubMed ID: 21679126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease.
    Li X; Wang QJ; Pan N; Lee S; Zhao Y; Chait BT; Yue Z
    PLoS One; 2011 Mar; 6(3):e17153. PubMed ID: 21390248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Leucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brain.
    Civiero L; Cirnaru MD; Beilina A; Rodella U; Russo I; Belluzzi E; Lobbestael E; Reyniers L; Hondhamuni G; Lewis PA; Van den Haute C; Baekelandt V; Bandopadhyay R; Bubacco L; Piccoli G; Cookson MR; Taymans JM; Greggio E
    J Neurochem; 2015 Dec; 135(6):1242-56. PubMed ID: 26375402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of LRRK2 kinase dysfunction in Parkinson disease.
    Kumar A; Cookson MR
    Expert Rev Mol Med; 2011 Jun; 13():e20. PubMed ID: 21676337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization.
    Sen S; Webber PJ; West AB
    J Biol Chem; 2009 Dec; 284(52):36346-36356. PubMed ID: 19826009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2).
    Beylina A; Langston RG; Rosen D; Reed X; Cookson MR
    Stem Cell Res; 2021 May; 53():102354. PubMed ID: 34087985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways.
    Sancho RM; Law BM; Harvey K
    Hum Mol Genet; 2009 Oct; 18(20):3955-68. PubMed ID: 19625296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.